Contribution of Mitochondrial Reactive Oxygen Species to Chronic Hypoxia-Induced Pulmonary Hypertension
Antioxidants · 30.11.2023 · 12 (12) · 2060
DOI: 10.3390/antiox12122060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 30.11.2023. Verfasst von Simin Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, U.S. National Institutes of Health.
Abstract (Originalsprache)
Pulmonary hypertension (PH) resulting from chronic hypoxia (CH) occurs in patients with chronic obstructive pulmonary diseases, sleep apnea, and restrictive lung diseases, as well as in residents at high altitude. Previous studies from our group and others demonstrate a detrimental role of reactive oxygen species (ROS) in the pathogenesis of CH-induced PH, although the subcellular sources of ROS are not fully understood. We hypothesized that mitochondria-derived ROS (mtROS) contribute to enhanced vasoconstrictor reactivity and PH following CH. To test the hypothesis, we exposed rats to 4 weeks of hypobaric hypoxia (PB ≈ 380 mmHg), with control rats housed in ambient air (PB ≈ 630 mmHg). Chronic oral administration of the mitochondria-targeted antioxidant MitoQ attenuated CH-induced decreases in pulmonary artery (PA) acceleration time, increases in right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary arterial remodeling. In addition, endothelium-intact PAs from CH rats exhibited a significantly greater basal tone compared to those from control animals, as was eliminated via MitoQ. CH also augmented the basal tone in endothelium-disrupted PAs, a response associated with increased mtROS production in primary PA smooth muscle cells (PASMCs) from CH rats. However, we further uncovered an effect of NO synthase inhibition with Nω–nitro-L-arginine (L-NNA) to unmask a potent endothelial vasoconstrictor influence that accentuates mtROS-dependent vasoconstriction following CH. This basal tone augmentation in the presence of L-NNA disappeared following combined endothelin A and B receptor blockade with BQ123 and BQ788. The effects of using CH to augment vasoconstriction and PASMC mtROS production in exogenous endothelin 1 (ET-1) were similarly prevented by MitoQ. We conclude that mtROS participate in the development of CH-induced PH. Furthermore, mtROS signaling in PASMCs is centrally involved in enhanced pulmonary arterial constriction following CH, a response potentiated by endogenous ET-1.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vascular Physiology Group, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
ORCID-Profile: Joshua R Sheak, Nikki L Jernigan
Förderung
- NHLBI NIH HHS
- U.S. National Institutes of Health
Zitieren
APA
Yan, S., Sheak, J. R., Walker, B. R., Jernigan, N. L., & Resta, T. C. (2023). Contribution of Mitochondrial Reactive Oxygen Species to Chronic Hypoxia-Induced Pulmonary Hypertension. Antioxidants, 12(12), 2060. https://doi.org/10.3390/antiox12122060
Vancouver
Yan S, Sheak JR, Walker BR, Jernigan NL, Resta TC. Contribution of Mitochondrial Reactive Oxygen Species to Chronic Hypoxia-Induced Pulmonary Hypertension. Antioxidants. 2023;12(12):2060. doi:10.3390/antiox12122060
BibTeX
@article{Yan2023,
author = {Yan, Simin and Sheak, Joshua R and Walker, Benjimen R and Jernigan, Nikki L and Resta, Thomas C},
title = {Contribution of Mitochondrial Reactive Oxygen Species to Chronic Hypoxia-Induced Pulmonary Hypertension},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {12},
pages = {2060},
doi = {10.3390/antiox12122060}
}
EUVIMED